Integrase Inhibitors: all 515 studies that test it

Page 3 of 6. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive SubjectsCompletedNCT00951015Phase 2Results posted
• A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to RaltegravirCompletedNCT00950859Phase 2Results posted
• Switch From Tenofovir to Raltegravir for Low Bone Mineral DensityCompletedNCT00939874Phase 4Results posted
• BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.CompletedNCT00931801Phase 4Results posted
• A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenCompletedNCT00931463Phase 4Results posted
• Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)CompletedNCT00920426Phase 2Results posted
• Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard TherapyCompletedNCT00887653Phase 3Results posted
• Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the GutCompletedNCT00884793Not applicableResults posted
• Buprenorphine/Raltegravir Pharmacokinetic Interaction StudyCompletedNCT00858962Not applicableResults posted
• Effect of Raltegravir on Endothelial Function in HIV-Infected PatientsCompletedNCT00843713Phase 4Results posted
• Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected AdultsCompletedNCT00830804Phase 2Results posted
• Pilot Study of a Raltegravir Based NRTI Sparing RegimenCompletedNCT00814879Not applicableResults posted
• Comparative Study of Three NNRTI-Sparing HAART RegimensCompletedNCT00811954Phase 3Results posted
• An Interaction Study to Assess Drug Levels in Fasting Healthy Adult SubjectsCompletedNCT00802074Not applicableResults posted
• Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell ResponseCompletedNCT00772590Phase 4Results posted
• Phase IIB Pilot of Atazanavir + RaltegravirTerminatedNCT00768989Phase 2Results posted
• A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)CompletedNCT00764946Phase 3Results posted
• Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected PatientsCompletedNCT00762892Phase 4Results posted
• Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive PatientsCompletedNCT00752856Phase 2Results posted
• A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)TerminatedNCT00745823Phase 3Results posted
• Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and WomenCompletedNCT00745368Not applicableResults posted
• Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 InfectionCompletedNCT00734344Not applicableResults posted
• Genetic Predictors of Raltegravir Penetration Into Cerebrospinal FluidCompletedNCT00729924Phase 2/3Results posted
• Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)CompletedNCT00711009Phase 3Results posted
• Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirCompletedNCT00708162Phase 3Results posted
• Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected AdultsCompletedNCT00708110Phase 2Results posted
• Kaletra-isentress Treatment EvaluationCompletedNCT00700115Phase 4Results posted
• Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 PatientsCompletedNCT00672932Not applicableResults posted
• A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy SubjectsCompletedNCT00666705Phase 4Results posted
• Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir TherapyCompletedNCT00661960Not applicableResults posted
• Raltegravir Therapy for Women With HIV and Fat AccumulationCompletedNCT00656175Phase 2Results posted
• Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive SubjectsCompletedNCT00654147Phase 2Results posted
• Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive IndividualsTerminatedNCT00632970Phase 4Results posted
• Raltegravir Intensification in HIV-infected PatientsCompletedNCT00631449Phase 4Results posted
• Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level ViremiaCompletedNCT00618371Not applicableResults posted
• An Interaction Study to Assess Drug Levels in Healthy Adult SubjectsCompletedNCT00614991Not applicableResults posted
• MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV InfectionTerminatedNCT00614458Phase 2Results posted
• HIV Non Occupational Post-Exposure Prophylaxis (PEP)CompletedNCT00594646Phase 4Results posted
• Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedNCT00537394Phase 3Results posted
• Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected SubjectsCompletedNCT00529243Phase 3Results posted
• Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)CompletedNCT00525733Not applicableResults posted
• RAL-eve Study: Raltegravir Substitution StudyCompletedNCT00523237Not applicableResults posted
• Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral LoadCompletedNCT00515827Phase 2Results posted
• A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected PatientsTerminatedNCT00488059Phase 4Results posted
• Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and AdolescentsCompletedNCT00485264Phase 1/2Results posted
• Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 InfectionCompletedNCT00445146Phase 2Results posted
• MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)TerminatedNCT00443729Phase 3Results posted
• MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)TerminatedNCT00443703Phase 3Results posted
• A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)CompletedNCT00369941Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)CompletedNCT00293267Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)CompletedNCT00293254Phase 3Results posted
• Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)CompletedNCT00105157Phase 2Results posted
• A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)CompletedNCT07532304Phase 1
• Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVActive, not recruitingNCT07055451Phase 1
• A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)CompletedNCT07002229Phase 1
• A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVActive, not recruitingNCT06970223Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsActive, not recruitingNCT06786520Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Active, not recruitingNCT06741397Phase 2
• RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II TrialTerminatedNCT06658977Phase 3
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Active, not recruitingNCT06630286Phase 3
• Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeNCompletedNCT06629480Not applicable
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedTerminatedNCT06613685Phase 2/3
• Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedActive, not recruitingNCT06544733Phase 2/3
• Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Active, not recruitingNCT06532656Phase 2/3
• Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting AntiretroviralsActive, not recruitingNCT06507059Phase 3
• Bioequivalence Study to Compare Dolutegravir 50mg Film-coated TabletsCompletedNCT06450275Phase 1
• B/F/TAF to DTG/3TC Switch StudyActive, not recruitingNCT06444620Phase 3
• Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social NeedsActive, not recruitingNCT06411223Phase 2
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyActive, not recruitingNCT06333808Phase 3
• Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+RilpivirineCompletedNCT06185452Phase 4
• Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)CompletedNCT06177574Phase 4
• Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South AfricaActive, not recruitingNCT06138600Phase 3
• Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Active, not recruitingNCT06134362Phase 3
• Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.CompletedNCT06061536Phase 2
• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingNCT05996471Phase 2
• UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for ChildrenCompletedNCT05993767Phase 2
• Combined Injectable Treatment for HIV and OUDWithdrawnNCT05991622Phase 2
• Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in BotswanaActive, not recruitingNCT05986084Phase 4
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingNCT05979311Phase 3
• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyCompletedNCT05917509Phase 3
• Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral LoadCompletedNCT05898841Phase 4
• Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected AdultsCompletedNCT05602506Phase 4
• Improving HIV-1 Control in Africa With Long Acting AntiretroviralsCompletedNCT05546242Phase 3
• Doravirine and Weight Gain in Antiretroviral NaiveWithdrawnNCT05457530Phase 3
• Effect of Dolutegravir Intensification on HIV-1 ReservoirsCompletedNCT05351684Phase 2
• Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot StudyWithdrawnNCT05295394Phase 4
• BFTAF Elderly Switch StudyCompletedNCT05243602Phase 4
• Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and DolutegravirCompletedNCT05236530Phase 1
• Triumeq in Amyotrophic Lateral SclerosisTerminatedNCT05193994Phase 3
• Long-Acting Treatment in Adolescents (LATA)Status unknownNCT05154747Phase 3
• Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of AgeStatus unknownNCT05147740Phase 4
• Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)Active, not recruitingNCT05122767Phase 1/2
• Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 InfectionActive, not recruitingNCT05122754Phase 4
• A Study of a Rilpivirine Extended-Release Suspension in Healthy ParticipantsCompletedNCT05112939Phase 1
• Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)CompletedNCT05030025Early Phase 1
• Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)Status unknownNCT04979468Phase 3
• The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy VolunteersCompletedNCT04950530Phase 1
• Efficacy, Tolerability and Acceptability of Biktarvy by TPLWHTerminatedNCT04944654Phase 4
• Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIVActive, not recruitingNCT04910711Phase 4
• Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected IndividualsCompletedNCT04904406Phase 4

← Integrase Inhibitors overview